(Q36429607)

14 August 2017

1 reference

title

Clinical activity of pemetrexed: a multitargeted antifolate anticancer agent (English)

1 reference

14 August 2017

Benjamin Solomon

1

1 reference

14 August 2017

Paul A Bunn

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

14 August 2017

1 reference

14 August 2017

volume

1

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

733-746

1 reference

Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Molecular, biochemical, and cellular pharmacology of pemetrexed

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Understanding the cancer biology universe: enigmas, context and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Pemetrexed safety and dosing strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

The ALPI Trial: the Italian/European experience with adjuvant chemotherapy in resectable non-small lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Pemetrexed (Alimta) in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Pemetrexed in bladder, head and neck, and cervical cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Gemcitabine in transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

A phase II trial of pemetrexed in patients with metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.6.733

21 January 2018

Identifiers

DOI

10.2217/14796694.1.6.733

1 reference

14 August 2017

1 reference